RT Journal Article
SR Electronic
T1 Clinical performance characteristics of the Swift Normalase Amplicon Panel for sensitive recovery of SARS-CoV-2 genomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.22.21265255
DO 10.1101/2021.10.22.21265255
A1 Shrestha, Lasata
A1 Lin, Michelle J.
A1 Xie, Hong
A1 Mills, Margaret G.
A1 Bakhash, Shah A. Mohamed
A1 Gaur, Vinod P.
A1 Livingston, Robert J.
A1 Castor, Jared
A1 Bruce, Emily A.
A1 Botten, Jason W.
A1 Huang, Meei-Li
A1 Jerome, Keith R.
A1 Greninger, Alexander L.
A1 Roychoudhury, Pavitra
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.22.21265255.abstract
AB Amplicon-based sequencing methods have been central in characterizing the diversity, transmission and evolution of SARS-CoV-2, but need to be rigorously assessed for clinical utility. Here, we validated the Swift Biosciences’ SARS-CoV-2 Swift Normalase Amplicon Panels using remnant clinical specimens. High quality genomes meeting our established library and sequence quality criteria were recovered from positive specimens with a 95% limit of detection of ≥ 40.08 SARS-CoV-2 copies/PCR reaction. Breadth of genome recovery was evaluated across a range of Ct values (11.3 – 36.7, median 21.6). Out of 428 positive samples, 406 (94.9%) generated genomes with < 10% Ns, with a mean genome coverage of 13,545X ± SD 8,382X. No genomes were recovered from PCR-negative specimens (n = 30), or from specimens positive for non-SARS-CoV-2 respiratory viruses (n = 20). Compared to whole-genome shotgun metagenomic sequencing (n = 14) or Sanger sequencing for the spike gene (n = 11), pairwise identity between consensus sequences was 100% in all cases, with highly concordant allele frequencies (R2 = 0.99) between Swift and shotgun libraries. When samples from different clades were mixed at varying ratios, expected variants were detected even in 1:99 mixtures. When deployed as a clinical test, 268 tests were performed in the first 23 weeks with a median turnaround time of 11 days, ordered primarily for outbreak investigations and infection control.Competing Interest StatementALG reports contract testing from Abbott Laboratories and research support from Gilead and Merck, outside of the described work. All other authors report no other financial or non-financial competing interests for this work.Funding StatementThis work was supported by NIH AI027757 to P.R. and NIH P30GM118228-04 to E.A.B. Computational analyses were supported by Fred Hutch Scientific Computing (NIH ORIP grant S10OD028685).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Washington approved this work and provided a waiver of informed consent for the use of deidentified patient specimens in this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and sequences have been deposited to GISAID.